Figure 3

SCM-198 inhibited lipopolysaccharide(LPS)-induced c-Jun N-terminal kinase (JNK) phosphorylation and IкB-к degradation in BV-2 cells. Exposure of BV-2 cells to 1 μg/ml LPS led to a time-dependent IкB-к degradation (a, b) and phosphorylation of ERK (p-ERK) (a, c), JNK (p-JNK) (a, d) and p38 (p-p38) (a, e). BV-2 cells were pretreated with 0.1 to 10 μM SCM, 100 μM ibuprofen (IBU), 10 μM SP600125 (SP), 10 μM PD98059 (PD), or 20 μM SB203580 (SB) for 2 hours, followed by 30-minute LPS stimulation. SCM could inhibit JNK activation (f, g) and IкB-к degradation (f, j), but not ERK (f, h) and p38 activation (f, i). Data represent mean ± SEM of more than three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, Tukey’s test versus only LPS-treated group; #P < 0.05, ##P < 0.01, ###P < 0.001, Tukey’s test versus control group.